Anne-Laure Flamar1, Yaming Xue, Sandra M Zurawski, Monica Montes, Bryan King, Louis Sloan, SangKon Oh, Jacques Banchereau, Yves Levy, Gerard Zurawski. 1. aBaylor Institute for Immunology Research, Dallas, Texas, USA bANRS HIV Vaccine Network/Vaccine Research Institute, Paris cEcole doctorale Sciences de la Vie et de la Santé, Université Paris-Est, Créteil, France dINSERM U899 eNorth Texas Infectious Diseases, Dallas, Texas, USA fUniversité Paris-Est, Faculté de Médecine, INSERM U955 gAssistance Publique-Hôpitaux de Paris, Groupe Henri-Mondor Albert-Chenevier, service d'immunologie clinique, Créteil, France.
Abstract
OBJECTIVE: Targeting HIV antigens directly to dendritic cells using monoclonal antibodies against cell-surface receptors has been shown to evoke potent cellular immunity in animal models. The objective of this study was to configure an anti-human CD40 antibody fused to a string of five highly conserved CD4 and CD8 T-cell epitope-rich regions of HIV-1 Gag, Nef and Pol (αCD40.HIV5pep), and then to demonstrate the capacity of this candidate therapeutic vaccine to target these HIV peptide antigens to human dendritic cells to expand functional HIV-specific T cells. METHODS: Antigen-specific cytokine production using intracellular flow cytometry and multiplex bead-based assay, and suppression of viral inhibition, were used to characterize the T cells expanded by αCD40.HIV5pep from HIV-infected patient peripheral blood mononuclear cell (PBMC) and dendritic cell/T-cell co-cultures. RESULTS: This candidate vaccine expands memory CD4 and CD8 T cells specific to multiple epitopes within all five peptide regions across a wide range of major histocompatibility complex (MHC) haplotypes from HIV-infected patient PBMC and dendritic cell/T-cell co-cultures. These in vitro expanded HIV antigen-specific CD4 and CD8 T cells produce multiple cytokines and chemokines. αCD40.HIV5pep-expanded CD8 T cells have characteristics of cytotoxic effector cells and are able to kill autologous target cells and suppress HIV-1 replication in vitro. CONCLUSION: Our data demonstrate the therapeutic potential of this CD40-targeting HIV candidate vaccine in inducing a broad repertoire of multifunctional T cells in patients.
OBJECTIVE: Targeting HIV antigens directly to dendritic cells using monoclonal antibodies against cell-surface receptors has been shown to evoke potent cellular immunity in animal models. The objective of this study was to configure an anti-humanCD40 antibody fused to a string of five highly conserved CD4 and CD8 T-cell epitope-rich regions of HIV-1Gag, Nef and Pol (αCD40.HIV5pep), and then to demonstrate the capacity of this candidate therapeutic vaccine to target these HIV peptide antigens to human dendritic cells to expand functional HIV-specific T cells. METHODS: Antigen-specific cytokine production using intracellular flow cytometry and multiplex bead-based assay, and suppression of viral inhibition, were used to characterize the T cells expanded by αCD40.HIV5pep from HIV-infectedpatient peripheral blood mononuclear cell (PBMC) and dendritic cell/T-cell co-cultures. RESULTS: This candidate vaccine expands memory CD4 and CD8 T cells specific to multiple epitopes within all five peptide regions across a wide range of major histocompatibility complex (MHC) haplotypes from HIV-infectedpatient PBMC and dendritic cell/T-cell co-cultures. These in vitro expanded HIV antigen-specific CD4 and CD8 T cells produce multiple cytokines and chemokines. αCD40.HIV5pep-expanded CD8 T cells have characteristics of cytotoxic effector cells and are able to kill autologous target cells and suppress HIV-1 replication in vitro. CONCLUSION: Our data demonstrate the therapeutic potential of this CD40-targeting HIV candidate vaccine in inducing a broad repertoire of multifunctional T cells in patients.
Authors: J Banchereau; F Briere; C Caux; J Davoust; S Lebecque; Y J Liu; B Pulendran; K Palucka Journal: Annu Rev Immunol Date: 2000 Impact factor: 28.527
Authors: G Pialoux; H Gahéry-Ségard; S Sermet; H Poncelet; S Fournier; L Gérard; A Tartar; H Gras-Masse; J P Levy; J G Guillet Journal: AIDS Date: 2001-07-06 Impact factor: 4.177
Authors: J E Schmitz; M J Kuroda; S Santra; V G Sasseville; M A Simon; M A Lifton; P Racz; K Tenner-Racz; M Dalesandro; B J Scallon; J Ghrayeb; M A Forman; D C Montefiori; E P Rieber; N L Letvin; K A Reimann Journal: Science Date: 1999-02-05 Impact factor: 47.728
Authors: H Gahéry-Ségard; G Pialoux; B Charmeteau; S Sermet; H Poncelet; M Raux; A Tartar; J P Lévy; H Gras-Masse; J G Guillet Journal: J Virol Date: 2000-02 Impact factor: 5.103
Authors: E S Rosenberg; J M Billingsley; A M Caliendo; S L Boswell; P E Sax; S A Kalams; B D Walker Journal: Science Date: 1997-11-21 Impact factor: 47.728
Authors: G Pantaleo; S Menzo; M Vaccarezza; C Graziosi; O J Cohen; J F Demarest; D Montefiori; J M Orenstein; C Fox; L K Schrager Journal: N Engl J Med Date: 1995-01-26 Impact factor: 91.245
Authors: X Jin; D E Bauer; S E Tuttleton; S Lewin; A Gettie; J Blanchard; C E Irwin; J T Safrit; J Mittler; L Weinberger; L G Kostrikis; L Zhang; A S Perelson; D D Ho Journal: J Exp Med Date: 1999-03-15 Impact factor: 14.307
Authors: Jens Dinter; Pauline Gourdain; Nicole Y Lai; Ellen Duong; Edith Bracho-Sanchez; Marijana Rucevic; Paul H Liebesny; Yang Xu; Mariko Shimada; Musie Ghebremichael; Daniel G Kavanagh; Sylvie Le Gall Journal: J Immunol Date: 2014-09-17 Impact factor: 5.422
Authors: John P Graham; Pierre Authie; Chun I Yu; Sandra M Zurawski; Xiao-Hua Li; Florentina Marches; Anne-Laure Flamar; Aditi Acharya; Jacques Banchereau; A Karolina Palucka Journal: Vaccine Date: 2016-08-29 Impact factor: 3.641
Authors: Sachin Gupta; James M Termini; Francesca N Raffa; Cindi-Ann Williams; Richard S Kornbluth; Geoffrey W Stone Journal: J Virol Date: 2013-11-13 Impact factor: 5.103